How is semaglutide dosed?
Semaglutide carries two injectable FDA labels — Ozempic and Wegovy — with different escalation lengths, maximums, and missed-dose windows. This page reads both side by side, the trials that add something neither label states on its own, and how research-grade semaglutide relates to both.
Topic: Comparing semaglutide’s two injectable FDA labels
Audience: Anyone comparing a semaglutide dosing figure against its actual label source
Reading time: 8–10 minutes
Not affiliated with Novo Nordisk
Prof. Peptide is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. This page reports what Novo Nordisk’s own prescribing information and FDA’s own publications state for both labels; it does not sell, ship, or recommend either branded product. Both labels describe a prescription pen or prefilled syringe, dispensed by a pharmacy — research-grade semaglutide, the material Prof. Peptide’s vendors sell, is neither of those products, described fully in the compounding section below.
On this page
- 1.What semaglutide is
- 2.Ozempic vs. Wegovy: the label schedules, compared
- 3.Trials that add something neither label states
- 4.Is there a research-grade dosing standard?
- 5.Compounding and research-grade semaglutide
- 6.How this page differs from the brand guides and the profile
- 7.Related pages
- 8.FAQ
- 9.References
What semaglutide is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, manufactured by Novo Nordisk. It has two injectable FDA-approved labels covering different indications: Ozempic (type 2 diabetes, cardiovascular risk, chronic kidney disease) and Wegovy (weight reduction and cardiovascular risk reduction, without a type 2 diabetes requirement). A third brand, Rybelsus, is an oral tablet with its own separate label and schedule — outside the injection-to-injection comparison this page focuses on. Ozempic and Wegovy share the same active ingredient and the same manufacturer, but each sets its own escalation schedule, cites its own trials, and carries its own missed-dose rule.
Prof. Peptide has already read each injectable label in full detail on its own page — how Ozempic is dosed and how Wegovy is dosed. This page exists to put them side by side, which neither brand page nor the semaglutide profile currently does in one table.
Ozempic vs. Wegovy: the label schedules, compared
Novo Nordisk, OZEMPIC (semaglutide) injection prescribing information, DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective May 19, 2026; Novo Nordisk, WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, effective June 18, 2026. Each brand’s own adverse-event figures sit directly under that brand’s dosage table, at its own reported dose, rather than in a separate section.
Ozempic
full Ozempic dosing guide- Indication
- Type 2 diabetes: glycemic control; cardiovascular risk reduction in adults with established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
- Starting dosage
- 0.25 mg once weekly for 4 weeks (initiation, not for glycemic control)
- Escalation
- 0.5 mg after 4 weeks; 1 mg after at least 4 more weeks if additional glycemic control is needed
- Maintenance
- 1 mg once weekly is the label's chronic-kidney-disease maintenance dosage specifically; otherwise no separate maintenance step is named beyond the escalation path.
- Maximum dosage
- 2 mg once weekly, reached only after at least 4 weeks each at 0.5 mg and 1 mg
- Missed-dose window
- Administer within 5 days of the missed dose; beyond that, skip and resume the regular weekly schedule.
- Boxed warning wording
- “In rodents, semaglutide causes…”
- Trials cited in the label
- Monotherapy trial (NCT02054897), SUSTAIN 6 (NCT01720446), FLOW (NCT03819153).
Top adverse reactions reported
Across trial doses (0.5/1 mg, N=260/261): nausea 15.8%/20.3%, vomiting 5%/9.2%, diarrhea 8.5%/8.8% — versus 6.1%, 2.3%, and 1.9% on placebo.
Wegovy (injection)
full Wegovy dosing guide- Indication
- Weight reduction (with a reduced-calorie diet and increased activity) in adults with obesity, or overweight with a weight-related condition, and reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight — no type 2 diabetes requirement. A separate oral-tablet formulation exists with its own schedule, not covered in this comparison.
- Starting dosage
- 0.25 mg once weekly, weeks 1–4
- Escalation
- 0.5 mg (weeks 5–8), 1 mg (weeks 9–12), 1.7 mg (weeks 13–16) — four steps versus Ozempic's two
- Maintenance
- 2.4 mg (recommended) or 1.7 mg once weekly from week 17; if 2.4 mg is tolerated ≥ 4 weeks and additional weight reduction is clinically indicated, the label permits escalation to a 7.2 mg maximum — a dose Ozempic's label has no equivalent of.
- Maximum dosage
- 7.2 mg once weekly for weight reduction (optional, beyond the 2.4 mg recommended dosage); no escalation past 2.4 mg described for cardiovascular risk reduction specifically
- Missed-dose window
- Administer as soon as possible only if the next dose is more than 2 days away; otherwise skip. Two or more consecutive missed doses restart the escalation from a lower dosage — a shorter window and a stricter restart rule than Ozempic's label.
- Boxed warning wording
- “In rodents, semaglutide causes…”
- Trials cited in the label
- Study 1 (NCT03574597, publicly known as SELECT), Study 2 (NCT03548935).
Top adverse reactions reported
At the 2.4 mg dose: nausea 44%, diarrhea 30%, vomiting 24%, constipation 24% — versus 16%, 16%, 6%, and 11% on placebo.
Both labels start at the same 0.25 mg once-weekly dosage, and that is where the similarity mostly ends. Ozempic’s label reaches its 2 mg maximum in two steps, each requiring at least 4 weeks; Wegovy’s label takes four steps over 16 weeks to reach a 2.4 mg recommended maintenance dosage, with an optional fifth step to a 7.2 mg maximum that Ozempic’s label has no equivalent of at all. The missed-dose rules are not interchangeable either: Ozempic allows 5 days before a dose is skipped, while Wegovy allows only 2 days and additionally requires restarting the escalation at a lower dosage after two or more consecutive missed doses — a rule with no parallel on Ozempic’s label. A reader applying one label’s missed-dose window to the other brand would be following the wrong rule.
Trials that add something neither label states
Each label cites its own trial program — the monotherapy trial, SUSTAIN 6, and FLOW for Ozempic; Study 1 through Study 10 (publicly known as STEP) for Wegovy. Two published trials sit outside both labels entirely and answer questions neither one does:
SURMOUNT-5 (NCT05822830)
72-week, randomized, open-label, head-to-head trial
Arms: 751 adults with obesity or overweight, without type 2 diabetes, randomized to semaglutide (maximum tolerated dose, 1.7 or 2.4 mg) or tirzepatide (maximum tolerated dose, 10 or 15 mg), both once weekly subcutaneous.
Endpoint reported: Body weight change at week 72: 13.7% with semaglutide vs. 20.2% with tirzepatide. GI-related discontinuation was also reported higher with semaglutide than tirzepatide in this trial. Neither Ozempic’s nor Wegovy’s own Clinical Studies section cites this trial — it directly compares semaglutide against a different compound, outside what either label’s own trial program is designed to show.
Attributed — published (N Engl J Med, 2025) and registered with a checkable NCT number.
STEP 4 (NCT03548987)
Randomized-withdrawal trial: 20-week open-label semaglutide run-in, then 48-week double-blind semaglutide vs. placebo
Arms: 902 adults with overweight or obesity entered the run-in; those reaching the 2.4 mg target dose were randomized 2:1 to continue semaglutide or switch to placebo from week 20.
Endpoint reported: Among participants switched to placebo, mean weight regain was 11.6% of body weight over the following 48 weeks; those continuing semaglutide maintained their loss. Neither label’s escalation table addresses what happens to the dose response after stopping — this trial does.
Attributed — published (JAMA, 2021) and registered with a checkable NCT number.
Is there a research-grade dosing standard?
The semaglutide profile states that research-grade dosing protocols “mirror the approved schedule” and that “there are no separate research-grade dosing standards.” That sentence is Prof. Peptide’s own editorial summary, though — it carries no external citation of its own, and is not itself a reported community source.
Checked for a genuinely sourceable research-grade or community dosing convention distinct from either label’s own schedule above and did not find one — no vendor page, forum consensus, or published source reports a semaglutide protocol that differs from what Ozempic’s and Wegovy’s own labels already specify. That absence is reported here rather than treated as license to state the “mirrors the label” claim as independently verified fact — the same standard held on the tirzepatide guide and on retatrutide’s guide before it.
Compounding and research-grade semaglutide
Neither Ozempic’s nor Wegovy’s prescribing information mentions compounding — the word does not appear in either label. Everything in the comparison above describes a prescription drug product, manufactured by Novo Nordisk and dispensed by a pharmacy against a prescription.
Research-grade semaglutide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither branded product described above nor a pharmacy-compounded version of either. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.
Separately from either branded label, FDA has published its own position on compounded semaglutide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.
On April 30, 2026, FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed; as of this page’s last check, FDA had not published a final determination.
None of this changes what either label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here, at the compound level rather than under either brand alone, because a reader comparing research-grade semaglutide against the approved product should see, in one place, that both labels are governed by different rules from the research-grade material, and that the regulatory status of compounded semaglutide is itself unsettled.
How this page differs from the brand guides and the profile
How Ozempic is dosed and how Wegovy is dosed each read one label in full depth — a complete escalation table, boxed warning quoted verbatim, and a full adverse-reaction table, with a standalone warnings section and Wegovy’s guide additionally covering its oral-tablet form. Neither compares its own figures against the other brand’s in a table; each treats the other only in passing. This page is the one place both injectable schedules, both missed-dose windows, and both boxed-warning wordings sit in the same table, with adverse events placed next to each brand’s own dose rather than in a separate section.
The semaglutide profile is a different kind of page again: it covers the molecule’s mechanism and the published trial evidence across all three brands (including Rybelsus), without reading either injectable label’s escalation table, missed-dose rule, or ADR table in the detail either brand guide or this page does. This page exists because comparing Ozempic’s and Wegovy’s dosing schedules directly — the specific figures that differ between them, especially the missed-dose window — is not something the profile’s FAQ-level summary or either brand guide’s single-label read currently does in one place.
FAQ
Is semaglutide the same as Ozempic or Wegovy?
Do Ozempic and Wegovy use the same dosing schedule?
Which trials does each label cite?
Is there a separate research-grade semaglutide dosing standard?
Is research-grade or compounded semaglutide the same as Ozempic or Wegovy?
References
- Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information. DailyMed, setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective 2026-05-19. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, setid ee06186f-2aa3-4990-a760-757579d8f77b, effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. ClinicalTrials.gov NCT05822830. https://clinicaltrials.gov/study/NCT05822830
- ClinicalTrials.gov. Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity Who Have Reached Target Dose During Run-in Period (STEP 4), NCT03548987. https://clinicaltrials.gov/study/NCT03548987
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
We may earn commissions from peptide vendor affiliate links.